This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05507216
Recruitment Status : Recruiting
First Posted : August 18, 2022
Last Update Posted : April 24, 2024
Sponsor:
Information provided by (Responsible Party):
Abivax S.A.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: ABX464 Drug: Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 612 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Actual Study Start Date : December 21, 2022
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ABX464 50mg
Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
 Drug: ABX464
Administered once daily in the morning with food
Other Name: Obefazimod
Experimental: ABX464 25mg
Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
 Drug: ABX464
Administered once daily in the morning with food
Other Name: Obefazimod
Placebo Comparator: Placebo
Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
 Drug: Placebo
Administered once daily in the morning with food


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 [ Time Frame: 8 weeks ]
    To compare the efficacy of ABX464 versus placebo on clinical remission


Secondary Outcome Measures :
  1. Proportion of subjects who achieve endoscopic improvement at week 8 [ Time Frame: 8 weeks ]
    To compare the efficacy of ABX464 versus placebo on endoscopic improvement

  2. Proportion of subjects who achieve clinical response per MMS at week 8 [ Time Frame: 8 weeks ]
    To compare the efficacy of ABX464 versus placebo on clinical response as per MMS

  3. Proportion of subjects with symptomatic remission at week 8 [ Time Frame: 8 weeks ]
    To compare the efficacy of ABX464 versus placebo on symptomatic remission

  4. Proportion of subjects with HEMI per Geboes at week 8 [ Time Frame: 8 weeks ]
    To compare the efficacy of ABX464 versus placebo on histologic-endoscopic mucosal improvement (HEMI)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority. If these approvals have not been granted, only subjects ≥ 18 years old will be enrolled. To be eligible, adolescent subjects must weight ≥ 40 kg and meet the definition of Tanner Stage 5 at the screening visit.
  • Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met.
  • Documented diagnosis of UC > 90 days prior to baseline, confirmed by endoscopy and histology. Should histology results not be available at screening, results from biopsies taken at screening may be used.
  • Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).
  • Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA is not accepted).
  • Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to use highly effective contraception methods
  • Subjects able and willing to comply with study visits and procedures as per protocol.
  • Subjects should be affiliated to a health insurance policy whenever required by a participating country or state

Exclusion Criteria:

  • Subjects with ulcerative colitis limited to an isolated proctitis (≤ 15cm from anal verge).
  • Subjects with primary sclerosing cholangitis or autoimmune hepatitis.
  • Subjects who have failed on 5-ASA therapy only.
  • Subjects with CD or presence or history of fistula, indeterminate colitis, infectious/ischemic colitis or microscopic colitis (lymphocytic and collagenous colitis).
  • History or current evidence of toxic megacolon, fulminant colitis, bowel perforation.
  • History of colon cancer, past or current evidence of low grade or high grade colonic dysplasia and/or adenomatous polyps that have not been completely removed.
  • Recent or planned bowel surgery or history of proctocolectomy or partial colectomy or current stoma.
  • Subjects on antidiarrheals (e.g., loperamide, diphenoxylate with atropine, etc.).
  • Subjects on probiotics (e.g., Culturelle® [Lactobacillus GG, i-Health, Inc.], Saccharomyces boulardii).
  • Subjects who do not meet the washout period requirements prior to the screening endoscopy

  • Subjects with the following hematological and biochemical laboratory parameters obtained during the screening period:

    • Hemoglobin ≤ 8.0 g dL-1
    • Absolute neutrophil count < 750 mm-3
    • Platelets < 100,000 mm-3
    • Creatinine clearance < 50 mL.min-1 (Cockroft-Gault formula)
    • Total serum bilirubin > 1.5 x ULN
    • Alkaline phosphatase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2 x ULN

  • Subjects with the following conditions (infection):

    • Subjects with chronic or recurrent grade 3 or grade 4 infection, or with opportunistic infection within the last 2 months prior to screening.
    • Herpes zoster reactivation within the last 2 months prior to screening.
    • Subjects with active infection at screening or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 1 month of screening or during screening. Fungal infection of nail beds is allowed.
    • Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridium difficile toxin at screening. If C. difficile is positive, subject may be treated and retested ≥ 2 weeks after completing treatment.
    • Subjects with HIV infection.
    • Subjects having acute or chronic hepatitis B infection at screening (positive for hepatitis B surface antigen [HbsAg], or negative for HbsAg and positive for anti-hepatitis B core antibody in conjunction with detectable HBV DNA, or detectable HBV DNA).
    • Subjects having acute or chronic hepatitis C infection at screening as defined by positive for hepatitis C antibody (subjects successfully treated and without recurrence ≥ 1 year with no detectable HCV RNA [assessed centrally] are eligible).
    • Active tuberculosis (TB) or untreated latent TB are ruled out. For subjects with positive or intermediate QuantiFERON test see section 5.3.8.1 of the current study protocol.
  • Subjects with an uncontrolled ischemic heart disease and/or a history of congestive heart failure with New York Heart Association (NYHA) class 3 or 4 symptoms.
  • Subjects with a family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval [Fridericia or Bazett correction] >450 milliseconds for male and > 460 milliseconds for female).
  • Subjects with a history of torsade de pointe (TdP).
  • Acute or chronic of clinically relevant pulmonary, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history (note: treated autoimmune hypothyroidy and autoimmune diabetes are allowed).
  • History or active malignancy (subjects with a 5-year disease free survival are eligible).
  • Serious illness requiring hospitalization within 4 weeks prior to screening (except UC flare).
  • Subjects previously treated with ABX464.
  • Pregnant or breast-feeding women.
  • Illicit drug or alcohol abuse or dependence.
  • Subjects who received live vaccine within 3 months prior to screening and/or who's planning to receive such a vaccine during the study duration.
  • Use of any investigational or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer, and during the study.
  • Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05507216


Contacts
Layout table for location contacts
Contact: Sharon Skare, CPhil +33153830961 sharon.skare@abivax.com

Locations
Show Show 307 study locations
Sponsors and Collaborators
Abivax S.A.
Investigators
Layout table for investigator information
Principal Investigator: Severine Vermeire, MD, PhD UZ Leuven, Belgium
Principal Investigator: Bruce Sands, MD, PhD Mount Sinai Health System Digestive Disease Institute, New York USA
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Abivax S.A.
ClinicalTrials.gov Identifier: NCT05507216    
Other Study ID Numbers: ABX464-106
First Posted: August 18, 2022    Key Record Dates
Last Update Posted: April 24, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
 Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases